Crossmark Global Holdings Inc. Invests $231,000 in Progyny, Inc. (NASDAQ:PGNY)

Crossmark Global Holdings Inc. purchased a new position in shares of Progyny, Inc. (NASDAQ:PGNYGet Rating) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 6,210 shares of the company’s stock, valued at approximately $231,000.

Several other institutional investors also recently modified their holdings of the stock. State of Michigan Retirement System increased its holdings in shares of Progyny by 1.7% during the second quarter. State of Michigan Retirement System now owns 17,979 shares of the company’s stock worth $522,000 after buying an additional 300 shares in the last quarter. Securian Asset Management Inc. increased its holdings in shares of Progyny by 5.5% during the third quarter. Securian Asset Management Inc. now owns 6,810 shares of the company’s stock worth $252,000 after buying an additional 356 shares in the last quarter. Yousif Capital Management LLC increased its holdings in shares of Progyny by 1.1% during the first quarter. Yousif Capital Management LLC now owns 37,264 shares of the company’s stock worth $1,915,000 after buying an additional 392 shares in the last quarter. Xponance Inc. increased its holdings in shares of Progyny by 3.6% during the third quarter. Xponance Inc. now owns 11,594 shares of the company’s stock worth $430,000 after buying an additional 401 shares in the last quarter. Finally, Captrust Financial Advisors increased its holdings in shares of Progyny by 25.0% during the first quarter. Captrust Financial Advisors now owns 2,091 shares of the company’s stock worth $107,000 after buying an additional 418 shares in the last quarter. 86.12% of the stock is currently owned by institutional investors and hedge funds.

Progyny Trading Down 2.2 %

Shares of PGNY opened at $32.78 on Wednesday. The stock has a market capitalization of $3.04 billion, a P/E ratio of 78.05, a price-to-earnings-growth ratio of 4.22 and a beta of 1.59. The firm’s fifty day simple moving average is $32.52 and its two-hundred day simple moving average is $36.39. Progyny, Inc. has a 12 month low of $25.67 and a 12 month high of $53.10.

Progyny (NASDAQ:PGNYGet Rating) last issued its quarterly earnings results on Thursday, November 3rd. The company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $0.08. The business had revenue of $205.37 million for the quarter, compared to analysts’ expectations of $194.41 million. Progyny had a net margin of 6.00% and a return on equity of 14.14%. As a group, research analysts predict that Progyny, Inc. will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling at Progyny

In other Progyny news, Chairman David J. Schlanger sold 25,020 shares of the company’s stock in a transaction on Friday, November 4th. The shares were sold at an average price of $39.30, for a total transaction of $983,286.00. Following the sale, the chairman now owns 82,548 shares of the company’s stock, valued at $3,244,136.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Chairman David J. Schlanger sold 25,020 shares of the company’s stock in a transaction dated Friday, November 4th. The shares were sold at an average price of $39.30, for a total transaction of $983,286.00. Following the transaction, the chairman now owns 82,548 shares in the company, valued at $3,244,136.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Peter Anevski sold 3,920 shares of the company’s stock in a transaction dated Thursday, November 3rd. The shares were sold at an average price of $39.19, for a total transaction of $153,624.80. Following the transaction, the chief executive officer now owns 250,445 shares in the company, valued at approximately $9,814,939.55. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 56,975 shares of company stock valued at $2,116,168. 14.00% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on PGNY shares. JPMorgan Chase & Co. lowered their price target on shares of Progyny from $78.00 to $62.00 and set an “overweight” rating for the company in a report on Friday, November 18th. SVB Leerink reissued a “market perform” rating and issued a $34.00 price objective (down previously from $59.00) on shares of Progyny in a research note on Thursday, January 5th. TheStreet raised shares of Progyny from a “d+” rating to a “c” rating in a research note on Monday, October 24th. Finally, KeyCorp reduced their price objective on shares of Progyny from $55.00 to $45.00 and set an “overweight” rating on the stock in a research note on Monday, December 19th. One research analyst has rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.25.

Progyny Company Profile

(Get Rating)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

See Also

Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNYGet Rating).

Institutional Ownership by Quarter for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.